Categories

News

Process Optimization of the MeltonVEC™-Cell Fusion Kit (HVJ-E) Product
2026-04-22
This process optimization further enhanced product purity. Test results showed that the cell fusion efficiency exceeded 90%, while the issue of high solution viscosity was also significantly improved.
MeltonVEC-Sendai iPS Reprogramming Kit  (PBMCs) user manual has been updated.
2025-09-15
The updated manual for the new version and free iPSC kits for evaluation are now available, please check it out.​
Hyperacute rejection-engineered oncolytic virus for interventional clinical trial in refractory cancer patients(Newcastle disease virus with porcine a1,3GT gene )
2025-03-26
This study shows that recombinant NDV-GT, carrying the porcine a1,3GT gene, effectively treats metastatic cancer with a 90% disease control rate in clinical trials, demonstrating high safety, efficacy, and minimal immune response, highlighting its potential as an oncolytic virus therapy.
 Ghent University-G-FaST laboratory has successfully completed spindle-transfer experiments using our products-Cell Fusion Kit(HVJ-E)(MSV1002)
2025-02-05
The G-FaST laboratory at Ghent University in Belgium has successfully completed spindle-transfer experiments using our products. In January 2025, the Chinese Academy of Sciences in Shanghai also successfully tested spindle transplantation. It is recommended that the soaking time be less than 5 seconds.
 Cell Fusion Kit(HVJ-E) (MSV1002) has been successfully delivered to customers in multiple countries.
2024-12-19
The Cell Fusion Kit(HVJ-E) (MSV1002) has now been delivered to customers in multiple countries and regions,we sincerely thank our customers for their trust and support of our products. We will promptly optimize our products based on customer feedback to ensure that every customer successfully completes their experiments.
 A temperature-sensitive and less immunogenic Sendai virus for  efficient gene editing
2024-12-17
This study developed a temperature-sensitive and less immunogenic Sendai virus (ts SeV) for CRISPR-Cas9 delivery, achieving over 90% CCR5 editing in human CD34+ HSPCs and CD14+ monocytes, significantly inhibiting HIV-1 infection. The ts SeV offers a safe, efficient, and versatile platform for gene editing and personalized medicine.
Novel andeffective plasmid transfection  protocols for functional analysis of genetic  elements in humancardiac fibroblasts-Nov.2024
2024-12-11
This study develops an optimized plasmid transfection protocol for primary human cardiac fibroblasts, aiming to improve gene transfer efficiency and minimize toxicity. Despite an efficiency below 5%, the protocol supports experiments like luciferase assays and allows profiling of fibroblast and cardiac fibroblast markers (VIM, TCF21). The findings provide a valuable tool for advancing cardiovascular research.
 “All in one” lipid-polymer nanodelivery system for gene therapy of  ischemic diseases
2024-11-27
This study develops lipid-polymer hybrid nanocarriers (FLNPs) to enhance gene delivery for ischemic diseases. FLNPs improve gene transfection, avoid lysosomes, and target the nucleus. Loaded with Hepatocyte Growth Factor (pHGF) and Catalase (pCAT) plasmids, FLNPs boosted cell resistance to oxidative stress and improved recovery in a mouse ischemia model, without causing metabolic disturbances. FLNPs show promise for effective gene therapy in ischemia.

Contact Us

Technical inquiries and product quotation
FirstName *
LastName
Email *
Message *
Describe the question you would like to inquire about